Clinical Evaluation of Women Presenting with Low Libido and Determination of Whether Androgen Therapy Might Be Appropriate

Mary-Anne Papalia; Henry Burger

doi:10.1055/s-2006-939567

Seminars in Reproductive Medicine, Inhaltsverzeichnis

Semin Reprod Med 2006; 24(2): 086-096
DOI: 10.1055/s-2006-939567

Clinical Evaluation of Women Presenting with Low Libido and Determination of Whether Androgen Therapy Might Be Appropriate

Mary-Anne Papalia¹ , Henry Burger²

¹Endocrinologist, Women's Health Program, Department of Medicine, Monash University, Alfred Hospital, Prahran, Victoria, Australia
²Endocrinologist, Emeritus Director, Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia

Abstract

ABSTRACT

The assessment of female sexual dysfunction (FSD) is often challenging in the clinical setting. Although androgen deficiency is regarded as a major cause for FSD, the causes of this condition are multifactorial. Women presenting with FSD require thorough clinical evaluation to determine the cause of FSD. Androgen therapy should be used in women only when clinical and biochemical parameters indicate that FSD stems from androgen deficiency. This review outlines the various causes of FSD, clinical and biochemical investigations required to diagnose androgen deficiency, and options for treatment of the woman found to have androgen deficiency as a cause of FSD.

KEYWORDS

Androgens - female - sexual - dysfunction - evaluation

Volltext

Referenzen

REFERENCES

1 Laumann E O, Paik A, Rosen R C. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999; 281 537-544
2 Basson R, Berman J, Burnett A et al.. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000; 163 888-893
3 Bachmann G A, Bancroft J, Braunstein G et al.. Female androgen insufficiency: The Princeton Consensus Statement on definition, classification and assessment. Fertil Steril. 2002; 77 660-665
4 [No authors listed] . Androgen insufficiency in women. Proceedings of the Princeton Conference. Princeton, New Jersey. July 29, 2001. Fertil Steril. 2002; 77(suppl 4) S1-99
5 Shifren J L, Braunstein G, Simon J et al.. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000; 343 682-688
6 Braunstein G, Shifren J, Simon J, Lucas J, Rodenberg C, Watts N B. Testosterone patches for the treatment of low sexual desire in surgically menopausal women. Proceedings of the 14th Annual Meeting of the North American Menopause Society September 17-20, 2003 Miami Beach, FL;
7 Davis S R, McCloud P I, Strauss B JG, Burger H G. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995; 21 227-236
8 Lobo R, Rosen R C, Yang H-M, Block B, Van der Hoop R. Comparative effects of oral esterified estrogens with and without methyl testosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril. 2003; 79 1341-1352
9 Buster J E, Kingsberg S A, Aguirre O et al.. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005; 105 944-952
10 Miller K, Sesmilo G, Schiller A, Schonfeld D, Burton S, Klibanski A. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab. 2001; 86 561-567
11 Simon J A. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil Steril. 2002; 77(suppl 4) S77-S82
12 Arlt W, Callies F, Van Vlijmen J C et al.. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999; 341 1013-1020
13 Lovas K, Gebre-Medhin G, Trovik T et al.. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized parallel group clinical trial. J Clin Endocrinol Metab. 2003; 88 1112-1118
14 Laughlin G, Barrett-Connor E, Kritz-Silverstein D, Von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women. The Rancho Bernado Study. J Clin Endocinol Metab. 2000; 85 645-651
15 Davison S, Bell R, Donath S, Montalto J, Davis S. Androgen levels in adult females: changes with age, menopause and oophorectomy. J Clin Endocrinol Metab. 2005; 90 3847-3853
16 Zumoff B, Strain G W, Miller L K, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995; 80 1429-1430
17 Burger H G, Dudley E C, Cui J, Dennerstein L, Hooper J. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000; 85 2832-2838
18 Lasley B, Santoro N, Randolf J et al.. The relationship of circulating dehydroepiandrosterone, testosterone and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab. 2002; 87 3760-3767
19 Rannevik G, Jeppsson S, Johnell O. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas. 1986; 8 189-196
20 Bancroft J, Cawood E HH. Androgens and the menopause: a study of 40-60 year old women. Clin Endocrinol (Oxf). 1996; 45 577-587
21 Orentreich N, Brind J L, Rizer R L, Vogelman J H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984; 59 551-555
22 Nathorst-Boos J, von Schoultz H. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest. 1992; 34 97-101
23 Dennerstein L, Smith A, Morse C, Burger H. Sexuality and the menopause. J Psychsom Obstet Gynecol. 1994; 15 59-66
24 Frock J, Money J. Sexuality and the menopause. Psychother Psychosom. 1984; 42 177-181
25 McCoy N L, Davidson J M. A longitudinal study of the effects of menopause on sexuality. Maturitas. 1985; 7 203-210
26 Appelt H, Strauss B. Effects of antiandrogen treatment on the sexuality of women with hyperandrogenism. Psychother Psychosom. 1984; 42 177-181
27 Bixo M, Backstrom T, Winblad B, Andersson A. Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J Steroid Biochem Mol Biol. 1995; 55 297-303
28 Davis S R, Tran J. Testosterone influences libido and wellbeing. Trends Endocrinol Metab. 2001; 12 33-37
29 Davis S, Goldstat R, Papalia M et al.. Effects of aromatase inhibition on sexual function and wellbeing in postmenopausal women treated with testosterone: a randomized placebo controlled trial. Menopause. 2005; , In press
30 Davis S R, Davison S L, Donath S, Bell R J. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005; 294 91-96
31 Avis N Z, Zhao X, Johannes C B, Ory M, Brockwell S, Greendale G A. Correlates of sexual function among multi-ethnic middles-aged women: results from the Study of Women's Health Across the Nation (SWAN). Menopause. 2005; 12 385-398
32 Dennerstein L, Lehert P, Burger H. The Relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition. Fertil Steril. 2005; 84 174-180
33 Sodergard R, Backstrom T, Shanhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982; 16 801-810
34 Vermeulen A, Verdonck L, Kaufman M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84 3666-3672
35 Davis S, Humborstone A, Milne R, Evans A. Measurement of serum total testosterone levels after administration of testosterone can underestimate the amount of testosterone that has been absorbed. Proceedings of 85th Annual Meeting of The Endocrine Society June 19-22, 2003 Philadelphia, PA;
36 Braunstein G D. Androgen insufficiency in women: summary of critical issues. Fertil Steril. 2002; 77(suppl 4) S94-S99
37 Somboonporn W. Testosterone therapy for postmenopausal women: efficacy and safety. Semin Reprod Med. 2006; 24 115-124
38 Goldstat R, Briganti E, Tran J, Wolfe R, Davis S. Transdermal testosterone improves mood, well being and sexual function in premenopausal women. Menopause. 2003; 10 390-398
39 Johannsson G, Burman P, Wiren L et al.. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002; 87 2046-2052
40 Hunt P, Gurnell E, Huppert F. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000; 85 4650-4656
41 Davis S R, Burger H. Androgens and the postmenopausal woman. J Clin Endocrinol Metab. 1996; 81 2759-2763
42 Davis S R, Walker K Z, Strauss B J. Effects of estradiol with and without testosterone on body composition and relationships with lipids in post-menopausal women. Menopause. 2000; 7 395-401
43 Chlebowski R, Hendrix S, Langer R, Stefanick M, Gass M. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA. 2003; 289 3243-3253
44 Rossouw J E, Anderson G L, Prentice R L et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288 321-333
45 Beral V. Million Women Study Collaborators . Breast cancer and hormone replacement therapy in the Million Women Study. Lancet. 2003; 362 419-427
46 Anderson G L, Limacher M, Assaf A R et al.. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291 1701-1712
47 Dimitrakakis C, Zhou J, Bondy C A. Androgens and mammary growth and neoplasia. Fertil Steril. 2002; 77 s26-s33
48 Anderson K E, Sellers T A, Chen P L, Rich S S, Hong C P, Folsom A R. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer. 1997; 79 494-499
49 Birrell S N, Bentel J M, Hickey T E et al.. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995; 52 459-467
50 Slayden S M. Risks of menopausal androgen supplementation. Semin Reprod Endocrinol. 1998; 16 145-152
51 Westaby D, Ogle S J, Paradinas F J, Randell J B, Murray-Lyon I M. Liver damage from long-term methyltestosterone. Lancet. 1977; 2 262-263
52 Murray-Lyon I M, Westaby D, Paradinas F. Hepatic complications of androgen therapy. Gastroenterology. 1977; 73 1461
53 Hickok L R, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol. 1993; 82 919-924
54 Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab. 1986; 62 16-21
55 Buckler H M, McElhone K, Durrington P N, Mackness M I, Ludlam C A, Wu F CW. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf). 1998; 49 173-178
56 Urman B, Pride S M, Yuen H B. Elevated serum testosterone hirsutism and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol. 1991; 77 595-598
57 Gerritsma E J, Brocaar M P, Hakkesteegt M M, Birkenhager J C. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year. Clin Otolaryngol Allied Sci. 1994; 19 79-84
58 Barrett-Connor E, Young R, Notelovitz M et al.. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 1999; 44 1012-1020
59 Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther. 1997; 19 1070-1084
60 Morales A J, Nolan J J, Nelson J C, Yen S SC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994; 78 1360-1367
61 Baulieu E, Thomas G, Legrain S et al.. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000; 97 4279-4284
62 Moore R. Livial: a review of clinical studies. Br J Obstet Gynaecol. 2001; 106(suppl 19) 1-21
63 Morris E, Wilson P, Robinson J, Rymer J. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol. 1999; 106 954-959
64 Botsis D, Kassanos D, Kalogirou D, Antoniou G, Vitoratos N, Karakitsos P. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low dose oestrogen or tibolone treatment: a comparison. Maturitas. 1997; 26 57-62
65 Egarter C, Huber J, Leikermoser R et al.. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas. 1996; 23 55-62
66 Gambacciani M, Ciaponi M, Cappagli B et al.. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol. 2004; 18 9-16
67 Winkler U, Altkemper R, Kwee B, Helmond F, Coelingh Bennink H. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascades: a multicenter, double blind randomized study. Fertil Steril. 2000; 74 10-19
68 Gompel A, Siromachkova M, Lombat A et al.. Tibolone on normal and breast cancer cells. Eur J Cancer. 2000; 36(suppl 4) 76-77
69 Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998; 105 904-911
70 Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest. 2000; 20 101-107
71 Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric. 2004; 7 3-7
72 Castelo-Branco C, Vicente J, Figueras F et al.. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas. 2000; 34 161-168
73 Doren M, Rubig A, Coelingh Bennink H, Holzgreve W. Differential effects of the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001; 75 554-559
74 Rossouw J, Anderson G, Prentice R et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA. 2002; 288 321-333
75 Grady D, Herrington D, Bittner V, Blumenthal R S. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen-progestin Replacement Study follow up (HERS-II). JAMA. 2002; 288 49-57

Dr.
Mary-Anne PapaliaM.D. FRACP

Endocrinologist, Women's Health Program, Department of Medicine, Monash University, Alfred Hospital, Commercial Road, Prahran, Victoria 3181, Australia

eMail: mary-anne.papalia@med.monash.edu.au